A Major Step Forward for Retinitis Pigmentosa
For the inherited retinal disease (IRD) community, progress in regulatory milestones brings new hope, particularly for conditions that have historically lacked restorative treatment options. According to Ophthalmology Times Europe, Nanoscope Therapeutics has officially initiated a rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MCO-010, an investigational therapy designed to treat vision loss caused by retinitis pigmentosa (RP).
Key Details of the BLA Submission
According to the source material, the FDA has granted Nanoscope a rolling review for the BLA, allowing the company to submit completed modules incrementally. The first modules have already been submitted, and the complete BLA submission is anticipated to wrap up in early 2026. Furthermore, MCO-010 has received fast-track designation from the FDA, making the application eligible for priority review.
Notably, Nanoscope reports that this marks the first-ever BLA submitted to the FDA for a gene-agnostic gene therapy targeting a retinal disease. Unlike traditional gene therapies that correct specific genetic mutations, MCO-010 is designed as a gene-agnostic approach intended to address the broad genetic diversity associated with RP.
What This Means for Patients and Families
Retinitis pigmentosa is a leading cause of blindness in the working-age population in the United States, impacting more than 100,000 individuals and leaving over 25,000 legally blind. Because MCO-010 is designed to function independently of specific underlying gene mutations, it represents a potentially broad-reaching option for patients experiencing severe vision loss. Sulagna Bhattacharya, CEO and co-founder of Nanoscope, noted in a press release that the submission offers a potential path for individuals on a trajectory toward permanent blindness to have a chance to regain sight.
Looking Ahead
As the rolling review process moves forward, Nanoscope anticipates completing the remainder of the BLA submission by early 2026. The IRD community will be closely following these regulatory developments as the FDA evaluates the application under its fast-track and priority review framework.